Inflammatory cardiomyopathies: short- and long-term outcomes after heart transplantation-a protocol for a systematic

Emanuele Bobbio1,2, Marie Lingbrant3,4, Bright I Nwaru5

  • 1Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden. emanuele.bobbio@vgregion.se.

Heart Failure Reviews
|January 15, 2020
PubMed

Insights

Heart transplantation outcomes for giant cell myocarditis and cardiac sarcoidosis are unclear. This systematic review synthesizes evidence on survival and rejection in these patients post-transplant.

Area of Science:

  • Cardiology
  • Transplantation Immunology
  • Systematic Reviews

Background:

  • Outcomes of heart transplantation (HTx) for giant cell myocarditis (GCM) and cardiac sarcoidosis (CS) remain controversial.
  • Limited single-center data hinders comprehensive understanding of post-HTx results in these specific patient groups.

Purpose of the Study:

  • To systematically review and synthesize existing literature on HTx outcomes in patients with GCM or CS.
  • To compare the outcomes of HTx for GCM/CS against other transplant etiologies, focusing on survival, rejection, and recurrence.

Main Methods:

  • Comprehensive literature search across major databases (PubMed, Scopus, Web of Science, EMBASE, Google Scholar) up to December 2019.
  • Inclusion of observational and interventional population-based studies, with quality assessment using Newcastle-Ottawa and Cochrane tools.
  • Narrative synthesis and meta-analysis of homogenous study estimates, adhering to MOOSE guidelines.

Main Results:

  • This review aims to be the first synthesis of survival, acute cellular rejection, and disease recurrence data for GCM and CS patients undergoing HTx.
  • The synthesis will provide critical insights into the suitability of HTx for these challenging conditions.

Conclusions:

  • This systematic review and meta-analysis will clarify the efficacy and safety of heart transplantation for patients with giant cell myocarditis and cardiac sarcoidosis.
  • Findings will inform clinical decision-making and guide future research priorities in cardiac transplantation for rare cardiomyopathies.

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
255
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
293
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
383
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
310
Tissue Transplantation01:24

Tissue Transplantation

Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
821